MY ACCOUNT | NEWSLETTER |

Insurance company funds pet cancer research


Nationwide insurance is supporting cancer research in pets as part of November’s national pet cancer awareness month. The program will include analysis of the pets and breeds at highest risk for cancer and types of cancer based on filed claims.

"Nationwide members submitted claims for more than $49 million in 2020 for the diagnosis and treatment of cancer in their pets," said Dr. Jules Benson, Chief Veterinary Officer for Nationwide. "As pet lovers ourselves, we know the emotional impact behind these numbers, and that's why we're expanding our efforts in leveraging our industry-leading claims data to provide vital information to pet parents and veterinary teams alike."

Across a 6-year timeframe, claims for more than 1.5 million pets were made to Nationwide and were used in the analysis. According to analysis, the 100 most common purebred pets were most likely to have a cancer claim, whereas a mixed breed was 48% less probable to have a claim of cancer. 

Among dogs, the English Cocker Spaniel the probability of a cancer claim was 246% higher than other dogs. At the other end of the spectrum, the Shiba Inu breed had a 62% reduction in risk compared to overall average across dog breeds. 

By location based on insurance claims, the most common body areas for cancer to develop were skin, liver, lymph, spleen, and bone.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Like1
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top